摘要
耐碳青霉烯类肠杆菌(Carbapenem-resistant Enterobacteriaceae,CRE)是严重威胁公共健康的一类细菌,它的高感染性、高死亡性和高耐药性给临床治疗带来巨大挑战。头孢他啶/阿维巴坦(Ceftazidime/Avibactam,CAZ/AVI)是一种由头孢菌素类药物(头孢他啶)和β-内酰胺酶抑制剂(阿维巴坦)组成的复方制剂,用于治疗18岁及以上成年人复杂性腹腔内感染、复杂性尿路感染、医院获得性细菌性肺炎和呼吸机相关细菌性肺炎等,抗菌谱为耐药形势严峻的革兰阴性菌。本文从CRE耐药机制、CAZ/AVI作用机制、药物代谢动力学、抗菌谱、临床应用、不良反应、耐药性等方面进行综述,以期为临床用药提供参考。
In recent years,there has been an increase in the incidence of infections caused by Carbapenem-resistant Enterobacteriaceae.These have become a serious public health and clinical problem.Its high infectivity,high mortality and high drug resistance pose great challenges to clinical treatment.CAZ/AVI(ceftazidime/avibactam)is a combination of a cephalosporin and a beta-lactamase inhibitor,It’s indicated for the treatment of patients 18 years or older with the following infections caused by designated susceptible microorganisms,such as complicated intra-abdominal infections(CIAI)c,complicated urinary tract infections(CUTI),hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.This article reviews the resistance mechanism,mechanism of action,pharmacokinetics,antimicrobial spectrum,clinical efficacy,side effect,drug resistance of ceftazidime/avibactam for the treatment of Carbapenem-resistant Enterobacteriaceae,and provide a reference for clinical administration.
作者
唐青
芦起
Tang Qing;Lu Qi(Department of Neonatology,Ministry of Education Key Laboratory of Child Development and Disorders,National Clinical Research Center for Child Health and Disorders,China International Science and Technology Cooperation base of Child development and Critical Disorders,Children's Hospital of Chongqing Medical University,Chongqing Key Laboratory of Pediatrics,Chongqing Key Laboratory of Pediatrics,Chongqing 400014)
出处
《国外医药（抗生素分册）》
CAS
2021年第5期265-270,共6页
World Notes on Antibiotics
